Christina Mattina

Assistant Managing Editor at American Journal of Managed Care

Featured in: Favicon

ajmc.com

onclive.com Favicon

oncnursingnews.com Favicon

newsbreak.com Favicon

medicaleconomics.com Favicon

drugtopics.com Favicon

centerforbiosimilars.com Favicon

businessandamerica.com

Articles

Managed Care Reflections: A Q&A With Hoangmai H. Pham, MD, MPH

3 weeks ago | ajmc.com | Hoangmai Pham |Christina Mattina

Am J Manag Care. 2025;31(4):In Press_____AJMC: How has the concept of managed care and the conversations around it changed over the past 30 years? PHAM: On the positive side, it has become a familiar way of life for American consumers, so there isn’t the vilification that had been going on in the 1990s.
MDA Reflects on 75 Years of Research and the Precarious Times Ahead

1 month ago | ajmc.com | Christina Mattina

Neuromuscular disease researchers, clinicians, and advocates gathered to celebrate 75 years of progress at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas, but they also noted that these gains could be reversed if cuts to Medicaid and research funding proceed.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children

1 month ago | ajmc.com | Christina Mattina

Results from the phase 3 STEER study of intrathecal onasemnogene abeparvovec showed encouraging efficacy and safety data for children aged 2 to 17 years with spinal muscular atrophy (SMA), paving the way for much broader uptake of this disease-modifying gene therapy.1 The findings were presented in a late-breaking research session of the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas, held March 16-19, 2025.
Neurologists Share Tips for Securing Patient Access to Gene Therapies

1 month ago | businessandamerica.com | Christina Mattina

Transformative gene therapies for neuromuscular diseases won’t make it into patients’ hands without the tenacious efforts of clinicians, hospital administrators, and other advocates, experts said at a session of the 2025 Muscular Dystrophy Association Clinical & Scientific Conference in Dallas, Texas, as they shared their advice for driving the change to enable patients to receive these advances.
EMBARK Data Show Continued Improvements With DMD Gene Therapy

1 month ago | ajmc.com | Christina Mattina

Encouraging long-term outcomes were seen in patients with Duchenne muscular dystrophy (DMD) who received the gene therapy delandistrogene moxeparvovec (Elevidys; Sarepta) in the EMBARK trial, according to findings presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas, held March 16-19, 2025.
How Access to SMA Treatment Varies Globally and by Insurance Type

1 month ago | ajmc.com | Christina Mattina

Newly approved therapies for spinal muscular atrophy (SMA) hold the potential to modify the disease course and extend patients’ life spans, but research shows that patients have variable likelihoods of receiving these therapies based on their country of residence, age, and insurance coverage. These findings were presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas, held March 16-19, 2025.
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic

1 month ago | businessandamerica.com | Christina Mattina

As the number of gene therapy options to treat neuromuscular diseases like Duchenne muscular dystrophy (DMD) and spinal muscular atrophy grows, so will the need to strengthen the delivery infrastructure, understand the risk-benefit calculus, and gather data across age groups, according to panelists speaking at a session of the 2025 Muscular Dystrophy Association Clinical & Scientific Conference in Dallas, Texas.
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic

1 month ago | ajmc.com | Christina Mattina

As the number of gene therapy options to treat neuromuscular diseases like Duchenne muscular dystrophy (DMD) and spinal muscular atrophy grows, so will the need to strengthen the delivery infrastructure, understand the risk-benefit calculus, and gather data across age groups, according to panelists speaking at a session of the 2025 Muscular Dystrophy Association Clinical & Scientific Conference in Dallas, Texas.
Solving the Transition Conundrum as More Children With Muscular Dystrophy Live to Adulthood

1 month ago | businessandamerica.com | Christina Mattina

As gene therapies transform the care of muscular dystrophy, more and more patients are surviving with these diseases that used to kill patients before they reached adulthood.
For Neuromuscular Disease Community, an Era of Opportunities and Threats

1 month ago | ajmc.com | Christina Mattina

Between gene editing capabilities, artificial intelligence, platform technology to speed drug delivery, and the talent and dedication of those working in the neuromuscular disease field, “these are tremendous opportunities—there’s never been a better time—but we have enormous headwinds at the same time,” Robert Califf, MD, former FDA commissioner, said in his keynote address to kick off the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas.